Vascular BioSciences Will Present Results of “CAR Peptide Targeted Liposomes Loaded with an Admixture of Fasudil and DETA Nonoate for the Treatment of PAH”, and “A PAH Drug Ranking S
Vascular BioSciences Announces Publication of “A Bioinformatic Algorithm based on Pulmonary Endoarterial Biopsy for Targeted Pulmonary Arterial Hypertension Therapy” in the Current Issue of The Open R
Vascular BioSciences Announces Publication of “CAR Selectively Enhances the Pulmonary Vasodilatory Effect of Fasudil in a Microsphere Model of Pulmonary Hypertension” in the Current I
Vascular BioSciences Receives $2.7M STTR Fast-Track Grant for CAR Liposomes with VA Hospital of Northern California Vascular BioSciences will be collaborating with the VA Hospital of Northern Californ
Vascular BioSciences Announces New Preclinical Research Results Demonstrating Improved Pulmonary Hypertension and Sepsis Survival with CAR Peptide CEO of Vascular BioSciences, David Mann, makes connec
FDA Grants Vascular BioSciences Humanitarian Use Device (HUD) Designation to the Endoarterial Biopsy Catheter for Group 1 Pulmonary Arterial Hypertension Humanitarian Use Device (HUD) designation from
Vascular BioSciences Presented Results of CAR Peptide Targeted Augmentation of Chronic Prostanoid Treatment in PAH at the ATS Meeting in Dallas, Texas New data on beneficial effects of co-administrati
Vascular BioSciences Awarded $2 Million Phase II STTR Grant From NHLBI to Develop CAR Peptide as a Targeted Therapy for Pulmonary Hypertension Grant awarded in partnership with Brigham and Women’s Hos
Vascular BioSciences Awarded Up To $2.3 Million Fast-Track STTR Grant From NHLBI To Develop CAR Peptide For Pulmonary Hypertension Project to be Conducted in Collaboration with Brigham and Women’s Hos
Vascular BioSciences Announces Publication of “Assessment of microRNA and gene dysregulaton in pulmonary hypertension by endoarterial biopsy” in the Current Issue of Pulmonary Circulation Goleta, CA.,
Vascular BioSciences announces publication of “Challenges in the development of chronic pulmonary hypertension models in large animals” in the Current Issue of Pulmonary Circulation Goleta, CA., Febru
Vascular BioSciences’ Sepsis Research Wins Award at the 46th Annual Critical Care Congress of the Society of Critical Care Medicine Hydrocortisone Therapy with CAR Peptide Protects the Injured E
Vascular BioSciences congratulates VP of Communications, Dr. Susana Peinado, Ph.D., on being awarded her Doctorate from UCSB School of Communication Goleta, Ca, June 7, 2016 — Vascular BioSciences ann
Vascular BioSciences to Make Six Presentations at the American Thoracic Society in San Francisco from May 15 – May 18 Vascular BioSciences to present the full scope of its research efforts at this yea
Vascular BioSciences Named the 2015 Winner of the Buzz of Bio “Pipelines of Promise” Competition Goleta, CA, May 21, 2015 – On April 30, 2015, the Biotech International Organization (BIO) announ
The American Journal of Pathology Highlights “CAR Selectively Enhances Drug Efficacy in PAH” as a Featured Article in the February 2014 Issue Goleta, CA, February 5, 2014 – The American Journal of Pat
Vascular BioSciences Announces Online Publication of Scientific Article Describing First Orally Available Disease Homing Peptide That Can Selectively Enhance the Effects of Co-Administered Drugs Golet
Vascular BioSciences Awarded $1.2 Million Contract from the NHLBI’s Vascular Interventions/Innovations and Therapeutic Advances (VITA) Program to Develop CAR Peptide Therapeutic Adjuvant for PAH Targe
Vascular BioSciences announces publication of “Vascular Histomolecular Analysis By Sequential Endoarterial Biopsy in a Shunt Model of Pulmonary Hypertension” in the Current Issue of Pulmonary Circulat
Vascular BioSciences recently awarded a NIH SBIR/STTR Phase I Commercialization Assistance Award to develop the CAR peptide as a therapeutic adjuvant. Goleta, CA., October 11, 2012 – Vascular BioScien
Vascular BioSciences announces CEO David Mann will present “CAR Peptide, a Disease Selective Therapeutic Adjuvant For Targeted Drug Therapy” during the 7th Annual Therapeutic Peptide Symposium San Die
Vascular BioSciences announced today that Dr. Kalju Kahn, PhD, has been named head of Medicinal Chemistry Goleta, Calif., July 3, 2012 – Vascular BioSciences announced today that Dr. Kalju Kahn, PhD,
Vascular Biosciences announces publication of “Hemodynamic and Histologic Characterization of a Swine (Sus scrofa domestica) Model of Chronic Pulmonary Arterial Hypertension” Durnham, North Carolina,
Peptide-Directed Highly Selective Targeting of Pulmonary Arterial Hypertension” Selected by Faculty of 1000 Goleta, Calif., June 24, 2011 – A recently published paper from Vascular BioSciences (VBS) i
VBS Pharmaceuticals announces publication of “Peptide-Directed Highly Selective Targeting of Pulmonary Arterial Hypertension” Goleta, Calif., June 10, 2011 – VBS Pharmaceuticals, in collaboration with
David Mann, CEO of Vascular BioSciences, Presents Opening Remarks at the Southern California Undergraduate Research Conference in Chemistry and Biochemistry (SCURC) Santa Barbara, Calif., April 24, 20
Vascular BioSciences to Sponsor 2011 Southern California Undergraduate Research Conference in Chemistry and Biochemistry Santa Barbara, Calif., April 23, 2011 – Vascular BioSciences will be a major sp
Vascular BioSciences, In Collaboration with the University of South Alabama, Awarded Exploration/Development R21 Grant from the National Heart Lung Blood Institute of the National Institutes of Health
Vascular BioSciences Awarded Qualifying Therapeutic Discovery Project Grant to Develop CAR Peptide as a Therapeutic Adjuvant San Diego, CA, November 9, 2010 – Vascular BioSciences was awarded a grant
Vascular BioSciences Opens New Office and Pilot Catheter Manufacturing Facility in Goleta, California Goleta, Calif., January 8, 2010 – Vascular BioSciences announced today that it has opened a new of
Vascular BioSciences CEO David Mann Awarded New U.S. and European Patents for Endorterial Biopsy Catheterization Equipment Kit Invention San Diego, CA, February 18, 2009 – Vascular BioSciences announc
Abraham Rothman, M.D. to Present “Pulmonary Endoarterial Biopsy” at the Society for Cardiovascular Angiography and Interventions at the American College of Cardiology Annual Innovation in Intervention
Vascular BioSciences Awarded STTR Matching Grant from the State of North Carolina Durham, North Carolina, March 26, 2008 – Vascular BioSciences announced today it has been awarded a $100,000 STTR matc
Vascular BioSciences Awarded Phase 1 STTR Grant from the National Heart Lung Blood Institute of the National Institutes of Health for Pulmonary Hypertension Durham, North Carolina, February 1, 2008 –
Vascular BioSciences Moves Research and Development to North Carolina Durham, North Carolina, January 24, 2008 – Vascular BioSciences announced today that it has opened an office in Research Triangle,
Vascular BioSciences Announces Key Addition to Molecular Diagnostics Team: Dr. Roy Williams of Burnham Institute Brings Bioinformatics Expertise San Diego, Calif., October 12, 2007 – Vascular BioScien
Vascular BioSciences Extends Patent Portfolio: Signs Exclusive IP License Agreement with the Burnham Institute for Medical Research San Diego, Calif., February 28, 2007 – Vascular BioSciences announce
Vascular BioSciences announces a Cooperative Research And Development Agreement with the U.S. Army Institute of Surgical Research to Develop Diagnostic and Therapeutic Solutions Addressing Acute Respi
VBS Congratulates Erkki Ruoslahti, M.D., Ph.D., on Receiving the 2005 Japan Prize in Cell Biology in Tokyo, Japan San Diego, Calif., April 20, 2005 – Vascular BioSciences (www.vascularbiosciences.com)
VBS announces that Erkki Ruoslahti, MD, PhD, joins its Board of Advisors San Diego, Calif., December 3, 2003 – Vascular BioSciences (www.vascularbiosciences.com) announced today that Erkki Ruoslahti,
VBS Announces Lung Transplant Rejection Detection with the Endoarterial Biopsy Catheter in an Animal Model San Diego, Calif., April 15, 2003 – Vascular BioSciences (www.vascularbiosciences.com) announ